Takeda Pharmaceutical Company Limited (TAK)

NYSE: TAK · IEX Real-Time Price · USD
13.36
+0.12 (0.91%)
Apr 22, 2024, 4:00 PM EDT - Market closed
0.91%
Market Cap 41.92B
Revenue (ttm) 29.40B
Net Income (ttm) 1.26B
Shares Out 3.14B
EPS (ttm) 0.36
PE Ratio 36.78
Forward PE 23.04
Dividend $0.62 (4.64%)
Ex-Dividend Date Mar 27, 2024
Volume 1,561,333
Open 13.31
Previous Close 13.24
Day's Range 13.30 - 13.41
52-Week Range 13.11 - 17.11
Beta 0.54
Analysts Buy
Price Target 20.00 (+49.7%)
Earnings Date May 9, 2024

About TAK

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, ... [Read more]

Sector Healthcare
Founded 1781
Employees 49,095
Stock Exchange NYSE
Ticker Symbol TAK
Full Company Profile

Financial Performance

In 2022, TAK's revenue was 4.03 trillion, an increase of 12.85% compared to the previous year's 3.57 trillion. Earnings were 317.02 billion, an increase of 37.80%.

Financial numbers in JPY Financial Statements

Analyst Forecast

According to one analyst, the rating for TAK stock is "Buy" and the 12-month stock price forecast is $20.0.

Price Target
$20.0
(49.70% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs

TOKYO , April 22, 2024 /PRNewswire/ -- Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK, President and CEO; Christophe Weber, "Takeda"), Astellas Pharma Inc. (TSE: 4503, President and CEO: N...

21 hours ago - PRNewsWire

U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn's Disease

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) admi...

4 days ago - Business Wire

Takeda Announces New U.S. Corporate Social Responsibility Program Partners to Build Equity through STEM Education and Access to Nutritional Food

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced the selection of eight new U.S. non-profit organizations as grant recipients, as part of its $14.6 million commitment to i...

14 days ago - Business Wire

Empathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAE

Takeda's 'In Their Shoes' initiative illuminates the daily struggles of IBD patients in the UAE, fostering empathy and understanding among participants. DUBAI, UAE, March 27, 2024 /PRNewswire/ -- Take...

26 days ago - PRNewsWire

Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) today announced that its Board of Directors decided on March 26, 2024 (CET) to propose candidates for Board of Directors ...

27 days ago - Business Wire

Takeda Announces Approval of ADZYNMA® Intravenous Injection 1500 (apadamtase alfa /cinaxadamtase alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE: 4502/NYSE:TAK) today announced that the Japanese Ministry of Health, Labour and Welfare has approved the use of ADZYNMA (apadamtase alfa ...

27 days ago - Business Wire

Takeda Announces U.S. FDA Approval of Supplemental New Drug Application (sNDA) for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) ...

4 weeks ago - Business Wire

Advanced Infusion Care (AIC) Now Offers Takeda's GLASSIA® [Alpha1-Proteinase Inhibitor (Human)] and ARALAST® NP [Alpha1-Proteinase Inhibitor (Human)]

DALLAS--(BUSINESS WIRE)--AIC, a division of AIS Healthcare, now offers GLASSIA and ARALAST NP, manufactured by Takeda, for the treatment of adult patients with clinically evident emphysema due to seve...

5 weeks ago - Business Wire

Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced positive topline results from a Phase 2, randomized, double-blind, placebo-controlled study evaluating the ...

5 weeks ago - Business Wire

Japan's Takeda partners with India's Biological E. to boost dengue vaccine production

Japan's Takeda Pharmaceutical will scale up production of its dengue vaccine Qdenga through a partnership with Indian vaccines maker Biological E., the companies said on Tuesday.

7 weeks ago - Reuters

Takeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic Areas

CAMBRIDGE, Mass. & HYDERABAD, India--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) and Biological E. Limited (BE), a leading India-based Vaccines and Pharmaceutical Company, today announced a strategic ...

2 months ago - Business Wire

US FDA approves Takeda's therapy for allergic inflammation in esophagus

Drugmaker Takeda said on Monday the U.S. Food and Drug Administration has approved its therapy for a type of allergic inflammation of the esophagus, making it the first oral treatment for the conditio...

2 months ago - Reuters

FDA Approves Takeda's EOHILIA (budesonide oral suspension), the First and Only Oral Treatment in the U.S. for Eosinophilic Esophagitis (EoE)

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved EOHILIA (budesonide oral suspension), the fir...

2 months ago - Business Wire

Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in First Half of Fiscal Year 2024

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in 2024.

2 months ago - Business Wire

Takeda Announces Chief Financial Officer Succession

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) today announced that Costa Saroukos, chief financial officer, has decided to leave Takeda to return to his home-country o...

2 months ago - Business Wire

Takeda Announces Third-Quarter FY2023 Results; On-Track Towards Full-Year Management Guidance With Strong Momentum in Growth & Launch Products

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for the third quarter of fiscal year 2023 (period ended December 31, 2023). With year-t...

2 months ago - Business Wire

Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology Asset

Takeda Will Be Protagonist's Co-Development, U.S. Co-Commercialization Partner With 50:50 Profit Share, and With Exclusive Ex-U.S. Global Rights to Commercialize Rusfertide, Protagonist's Investigatio...

Other symbols: PTGX
2 months ago - Accesswire

Takeda's GAMMAGARD LIQUID® Approved by U.S. FDA for Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--U.S. Food and Drug Administration (FDA) approves GAMMAGARD LIQUID for adults with chronic inflammatory demyelinating polyneuropathy (CIDP).

3 months ago - Business Wire

Takeda's HYQVIA® Approved by European Commission as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda announced that the EC approved HYQVIA as maintenance therapy in patients of all ages with CIDP after stabilization with IVIG.

3 months ago - Business Wire

Cognizant Helping to Modernize Infrastructure and Application Management as Part of Takeda's Digital Transformation

Cognizant will support Takeda's ambition to modernize technology capabilities   TEANECK, N.J. , Jan. 25, 2024 /PRNewswire/ -- Cognizant (NASDAQ: CTSH) announced today an expanded agreement with Takeda...

Other symbols: CTSH
3 months ago - PRNewsWire

Takeda Named Global Top Employer for Seventh Consecutive Year

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda announced that it has received global Top Employer certification for 2024. It is one of just 17 companies that received global recognition.

3 months ago - Business Wire

U.S. FDA Approves Takeda's HYQVIA® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--U.S. Food and Drug Administration (FDA) approves HYQVIA for adults with chronic inflammatory demyelinating polyneuropathy (CIDP).

3 months ago - Business Wire

Takeda Announces China NMPA Approval of LIVTENCITY® (maribavir) for the Treatment of Adults With Post-transplant Cytomegalovirus (CMV) Refractory to Prior Therapies

OSAKA, Japan & CAMBRIDGE, Massachusetts--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that LIVTENCITY® (maribavir) has been approved by the National Medical Products Administration (NMP...

4 months ago - Business Wire

JCR Pharmaceuticals and Takeda Pharmaceuticals Announce Discontinuation of Gene Therapy Collaboration

HYOGO, Japan--(BUSINESS WIRE)--JCR announced the discontinuation of a collaboration with Takeda to develop gene therapies using AAV combined with the JCR J-Brain Cargo® Technology.

4 months ago - Business Wire

Takeda Receives Positive CHMP Opinion for HYQVIA® as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--The CHMP has recommended the approval of Takeda's HYQVIA in patients with CIDP as maintenance therapy after stabilization with IVIG.

4 months ago - Business Wire